FTC and DOJ Memorialize Joint Pharmaceutical Antitrust Enforcement Workshop

The ideas lined out in the workshop summary mimic some of the FTC’s recent positions regarding concentration in the pharmaceutical industry, including its efforts to gain insight into PBMs through the ongoing 6(b) study and its recent suit to block the Amgen-Horizon Therapeutics acquisition.

Related Keywords

Lina Khan ,Patricia Danzon ,Amgen ,Professor At Rutgers Law School ,Professor Of Health Care Management ,Amgen Inc ,Wharton School Of The University Pennsylvania ,Supreme Court ,Us Department Of Justice Antitrust Division ,Federal Trade Commission ,Justice Antitrust Division ,Agencie June ,Pharmaceutical Mergers ,Health Care Management ,Wharton School ,Horizon Therapeutics ,Innovation Aspects ,Bad Acts ,Pharmaceutical Merger ,Mitigation Strategy ,Rutgers Law School ,Amgen Horizon Therapeutics ,Legal ,Ood And Drug Law ,Pharmaceutical Regulation ,Antitrust And Trade Law ,Department Of Justice ,